Novo Nordisk's UBT251 Shows Promising Results in Phase 2 Trial for Type 2 Diabetes Treatment

Novo Nordisk's UBT251, a triple agonist of GLP-1, GIP, and glucagon, showed a mean HbA1c reduction of up to 2.16% and a mean body weight reduction of up to 9.8% after 24 weeks in a phase 2 trial in Chinese patients with type 2 diabetes. The safety profile was consistent with other triple-G agonist trials. UBT251 is being jointly developed by United Biotechnology and Novo Nordisk.